Recent trials in immunosuppression and their consequences for current therapy
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F14%3A00058996" target="_blank" >RIV/00023001:_____/14:00058996 - isvavai.cz</a>
Výsledek na webu
<a href="http://journals.lww.com/co-transplantation/pages/articleviewer.aspx?year=2014&issue=08000&article=00010&type=abstract" target="_blank" >http://journals.lww.com/co-transplantation/pages/articleviewer.aspx?year=2014&issue=08000&article=00010&type=abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MOT.0000000000000093" target="_blank" >10.1097/MOT.0000000000000093</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Recent trials in immunosuppression and their consequences for current therapy
Popis výsledku v původním jazyce
Purpose of review: Although the scarcity of clinical trials with de-novo immunosuppression has been typical over the last 2 years, several attempts have been made in drug conversion, dosing optimization, and bioequivalence. On the basis of recent clinical and animal studies, future directions of management and treatment are outlined. Recent findings: Studies with new tacrolimus formulations showed better bioavailability and lower doses, which might translate into less toxicity. The long-term results ofstudies with costimulation blockade confirmed their safety and efficacy. Calcineurin inhibitor (CNI)-free regimens based on mTOR inhibitors were shown to be associated with increased risk of the humoral response. Therefore, ongoing trials are predominantly designed to minimize calcineurin inhibitor dose only. Biologics, such as B-cell-specific agents (bortezomib and rituximab) and complement inhibitors (eculizumab) used to treat antibody-mediated rejection, recurrence of glomerulonephrit
Název v anglickém jazyce
Recent trials in immunosuppression and their consequences for current therapy
Popis výsledku anglicky
Purpose of review: Although the scarcity of clinical trials with de-novo immunosuppression has been typical over the last 2 years, several attempts have been made in drug conversion, dosing optimization, and bioequivalence. On the basis of recent clinical and animal studies, future directions of management and treatment are outlined. Recent findings: Studies with new tacrolimus formulations showed better bioavailability and lower doses, which might translate into less toxicity. The long-term results ofstudies with costimulation blockade confirmed their safety and efficacy. Calcineurin inhibitor (CNI)-free regimens based on mTOR inhibitors were shown to be associated with increased risk of the humoral response. Therefore, ongoing trials are predominantly designed to minimize calcineurin inhibitor dose only. Biologics, such as B-cell-specific agents (bortezomib and rituximab) and complement inhibitors (eculizumab) used to treat antibody-mediated rejection, recurrence of glomerulonephrit
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
EC - Imunologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current Opinion in Organ Transplantation
ISSN
1087-2418
e-ISSN
—
Svazek periodika
19
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
8
Strana od-do
387-394
Kód UT WoS článku
000339169400009
EID výsledku v databázi Scopus
—